MOLECURE/ PLONCTH00011 /
2024-10-11 5:01:49 PM | Chg. +0.18 | Volume | Bid9:10:00 PM | Ask9:10:00 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
11.04PLN | +1.66% | 23,368 Turnover: 257,292.02 |
-Bid Size: - | -Ask Size: - | 185.87 mill.PLN | - | - |
GlobeNewswire
05-21
Molecure receives approval to initiate a Phase II clinical trial (KITE) for OATD-01 for the treatmen...
GlobeNewswire
04-03
Molecure has published its financial report for 2023 - the company has significantly accelerated the...
GlobeNewswire
03-22
First patient in the UK is dosed in the OATD-01 Phase 2 KITE study in pulmonary sarcoidosis
GlobeNewswire
2023-11-02
Galapagos reports third quarter 2023 results and releases new encouraging data from CAR-T studies fo...
GlobeNewswire
2023-10-31
Molecure Announces Third Quarter 2023 Financial Results and Pipeline Highlights
GlobeNewswire
2023-09-29
Molecure Announces First Half 2023 Results – Significant Financial and Operating Momentum